跳至主要内容
临床试验/CTRI/2026/04/107424
CTRI/2026/04/107424尚未招募不适用

A Prospective Study to Evaluate the Efficacy and Safety of Injectable Platelet-Rich Fibrin (i-PRF) in the Management of Periorbital Aging Changes: Clinical, Dermoscopic, and Patient-Reported Outcome Assessment.

Datta Meghe Medical College1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2026年4月13日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
25
试验地点
1

研究概览

简要总结

The study aims to collect strong clinical and dermoscopic proof about how safe and effective

injectable Platelet-Rich Fibrin (i-PRF) is in treating periorbital aging. If it works well, it

might give people a low-cost and natural option instead of synthetic fillers or laser

treatments. The results could help create treatment guidelines and make it easier to include

regenerative therapies in day to day aesthetic dermatology practices.

研究设计

研究类型
Observational

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Adults aged 30–60 years with clinical signs of periorbital aging (e.g., fine lines, volume loss, and pigmentation).
  • Fitzpatrick skin types III–V.
  • Willingness to get i-PRF injections and attend follow-up appointments.
  • Participants who agree to take part in the study.

排除标准

  • Patients with active dermatological or systemic infections.
  • History of bleeding disorders or anticoagulant therapy.
  • Autoimmune diseases or immunosuppressed states.
  • History of cosmetic procedures (e.g., fillers, botulinum toxin) in the periorbital region in the past 6 months.
  • Pregnant or lactating women.
  • Known hypersensitivity to any materials used in the procedure.
  • Inability or unwillingness to comply with study protocol.

研究者

发起方
Datta Meghe Medical College
申办方类型
Private medical college
责任方
Principal Investigator
主要研究者

Manasi Mukund Joshi

Datta Meghe Medical College, Nagpur

研究点 (1)

Loading locations...

相似试验